Cargando…
Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots
[Image: see text] The emergence of double mutation delta (B.1.617.2) variants has dropped vaccine effectiveness against SARS-CoV-2 infection. Although COVID-19 is responsible for more than 5.4 M deaths till now, more than 40% of infected individuals are asymptomatic carriers as the immune system of...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886715/ https://www.ncbi.nlm.nih.gov/pubmed/35252734 http://dx.doi.org/10.1021/acsomega.2c00113 |
_version_ | 1784660737222770688 |
---|---|
author | Pramanik, Avijit Sharma, Poonam C. Patibandla, Shamily Gao, Ye Ruppa-Kasani, Vinod Goli, Jagruti Kumar, Animesh Chatterjee, Abhirup Sinha, Sudarson Sekhar Bates, John T. Bierdeman, Michael A. Tandon, Ritesh Ray, Paresh Chandra |
author_facet | Pramanik, Avijit Sharma, Poonam C. Patibandla, Shamily Gao, Ye Ruppa-Kasani, Vinod Goli, Jagruti Kumar, Animesh Chatterjee, Abhirup Sinha, Sudarson Sekhar Bates, John T. Bierdeman, Michael A. Tandon, Ritesh Ray, Paresh Chandra |
author_sort | Pramanik, Avijit |
collection | PubMed |
description | [Image: see text] The emergence of double mutation delta (B.1.617.2) variants has dropped vaccine effectiveness against SARS-CoV-2 infection. Although COVID-19 is responsible for more than 5.4 M deaths till now, more than 40% of infected individuals are asymptomatic carriers as the immune system of the human body can control the SARS-CoV-2 infection. Herein, we report for the first time that human host defense neutrophil α-defensin HNP1 and human cathelicidin LL-37 peptide-conjugated graphene quantum dots (GQDs) have the capability to prevent the delta variant virus entry into the host cells via blocking SARS-CoV-2 delta variant (B.1.617.2) spike protein receptor-binding domain (RBD) binding with host cells’ angiotensin converting enzyme 2 (ACE2). Experimental data shows that due to the binding between the delta variant spike protein RBD and bioconjugate GQDs, in the presence of the delta variant spike protein, the fluorescence signal from GQDs quenched abruptly. Experimental quenching data shows a nonlinear Stern–Volmer quenching profile, which indicates multiple binding sites. Using the modified Hill equation, we have determined n = 2.6 and the effective binding affinity 9 nM, which is comparable with the ACE2–spike protein binding affinity (8 nM). Using the alpha, beta, and gamma variant spike-RBD, experimental data shows that the binding affinity for the delta B.1.617.2 variant is higher than those for the other variants. Further investigation using the HEK293T-human ACE2 cell line indicates that peptide-conjugated GQDs have the capability for completely inhibiting the entry of delta variant SARS-CoV-2 pseudovirions into host cells via blocking the ACE2–spike protein binding. Experimental data shows that the inhibition efficiency for LL-37 peptide- and HNP1 peptide-attached GQDs are much higher than that of only one type of peptide-attached GQDs. |
format | Online Article Text |
id | pubmed-8886715 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-88867152022-03-01 Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots Pramanik, Avijit Sharma, Poonam C. Patibandla, Shamily Gao, Ye Ruppa-Kasani, Vinod Goli, Jagruti Kumar, Animesh Chatterjee, Abhirup Sinha, Sudarson Sekhar Bates, John T. Bierdeman, Michael A. Tandon, Ritesh Ray, Paresh Chandra ACS Omega [Image: see text] The emergence of double mutation delta (B.1.617.2) variants has dropped vaccine effectiveness against SARS-CoV-2 infection. Although COVID-19 is responsible for more than 5.4 M deaths till now, more than 40% of infected individuals are asymptomatic carriers as the immune system of the human body can control the SARS-CoV-2 infection. Herein, we report for the first time that human host defense neutrophil α-defensin HNP1 and human cathelicidin LL-37 peptide-conjugated graphene quantum dots (GQDs) have the capability to prevent the delta variant virus entry into the host cells via blocking SARS-CoV-2 delta variant (B.1.617.2) spike protein receptor-binding domain (RBD) binding with host cells’ angiotensin converting enzyme 2 (ACE2). Experimental data shows that due to the binding between the delta variant spike protein RBD and bioconjugate GQDs, in the presence of the delta variant spike protein, the fluorescence signal from GQDs quenched abruptly. Experimental quenching data shows a nonlinear Stern–Volmer quenching profile, which indicates multiple binding sites. Using the modified Hill equation, we have determined n = 2.6 and the effective binding affinity 9 nM, which is comparable with the ACE2–spike protein binding affinity (8 nM). Using the alpha, beta, and gamma variant spike-RBD, experimental data shows that the binding affinity for the delta B.1.617.2 variant is higher than those for the other variants. Further investigation using the HEK293T-human ACE2 cell line indicates that peptide-conjugated GQDs have the capability for completely inhibiting the entry of delta variant SARS-CoV-2 pseudovirions into host cells via blocking the ACE2–spike protein binding. Experimental data shows that the inhibition efficiency for LL-37 peptide- and HNP1 peptide-attached GQDs are much higher than that of only one type of peptide-attached GQDs. American Chemical Society 2022-02-22 /pmc/articles/PMC8886715/ /pubmed/35252734 http://dx.doi.org/10.1021/acsomega.2c00113 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Pramanik, Avijit Sharma, Poonam C. Patibandla, Shamily Gao, Ye Ruppa-Kasani, Vinod Goli, Jagruti Kumar, Animesh Chatterjee, Abhirup Sinha, Sudarson Sekhar Bates, John T. Bierdeman, Michael A. Tandon, Ritesh Ray, Paresh Chandra Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots |
title | Blocking SARS-CoV-2 Delta Variant (B.1.617.2)
Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor
of the Host Cell and Inhibiting Virus Infections Using Human Host
Defense Peptide-Conjugated Graphene Quantum Dots |
title_full | Blocking SARS-CoV-2 Delta Variant (B.1.617.2)
Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor
of the Host Cell and Inhibiting Virus Infections Using Human Host
Defense Peptide-Conjugated Graphene Quantum Dots |
title_fullStr | Blocking SARS-CoV-2 Delta Variant (B.1.617.2)
Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor
of the Host Cell and Inhibiting Virus Infections Using Human Host
Defense Peptide-Conjugated Graphene Quantum Dots |
title_full_unstemmed | Blocking SARS-CoV-2 Delta Variant (B.1.617.2)
Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor
of the Host Cell and Inhibiting Virus Infections Using Human Host
Defense Peptide-Conjugated Graphene Quantum Dots |
title_short | Blocking SARS-CoV-2 Delta Variant (B.1.617.2)
Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor
of the Host Cell and Inhibiting Virus Infections Using Human Host
Defense Peptide-Conjugated Graphene Quantum Dots |
title_sort | blocking sars-cov-2 delta variant (b.1.617.2)
spike protein receptor-binding domain binding with the ace2 receptor
of the host cell and inhibiting virus infections using human host
defense peptide-conjugated graphene quantum dots |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886715/ https://www.ncbi.nlm.nih.gov/pubmed/35252734 http://dx.doi.org/10.1021/acsomega.2c00113 |
work_keys_str_mv | AT pramanikavijit blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots AT sharmapoonamc blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots AT patibandlashamily blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots AT gaoye blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots AT ruppakasanivinod blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots AT golijagruti blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots AT kumaranimesh blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots AT chatterjeeabhirup blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots AT sinhasudarsonsekhar blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots AT batesjohnt blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots AT bierdemanmichaela blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots AT tandonritesh blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots AT raypareshchandra blockingsarscov2deltavariantb16172spikeproteinreceptorbindingdomainbindingwiththeace2receptorofthehostcellandinhibitingvirusinfectionsusinghumanhostdefensepeptideconjugatedgraphenequantumdots |